• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>BMC Software

BMC Software

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Cloud Security Market Size and Trend Analysis 2014 - 2024 - Research and Markets

    Cloud Security Market Size and Trend Analysis 2014 - 2024 - Research and Markets

  2. Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer

    Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer

  3. Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium

    Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium

  4. Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

    Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

  5. Chi-Med appoints Industry Veteran Paul Carter to Board of Directors

    Chi-Med appoints Industry Veteran Paul Carter to Board of Directors

  6. Terry Arnold Joins Southern Glazer’s Wine & Spirits as Senior Vice President, Human Resources

    Terry Arnold Joins Southern Glazer’s Wine & Spirits as Senior Vice President, Human Resources

  7. Sleep Apnea Diagnostic System Market 2016-2026: Transition from Diagnostic Testing to Integrated Care is a Key Future Trend - Research and Markets

    Sleep Apnea Diagnostic System Market 2016-2026: Transition from Diagnostic Testing to Integrated Care is a Key Future Trend - Research and Markets

  8. UPDATE: Don't touch anything without gloves this holiday season -- not even soap

    UPDATE: Don't touch anything without gloves this holiday season -- not even soap

  9. UPDATE: Don't touch anything without gloves this holiday season -- not even soap

    UPDATE: Don't touch anything without gloves this holiday season -- not even soap

  10. Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy

    Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.